CN111481550A - Pharmaceutical formulation containing tiotropium bromide and arformoterol - Google Patents
Pharmaceutical formulation containing tiotropium bromide and arformoterol Download PDFInfo
- Publication number
- CN111481550A CN111481550A CN202010406777.3A CN202010406777A CN111481550A CN 111481550 A CN111481550 A CN 111481550A CN 202010406777 A CN202010406777 A CN 202010406777A CN 111481550 A CN111481550 A CN 111481550A
- Authority
- CN
- China
- Prior art keywords
- arformoterol
- compound
- tiotropium bromide
- pharmaceutical formulation
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Abstract
The invention provides a medicinal preparation containing tiotropium bromide and arformoterol, which comprises tiotropium salt or hydrate thereof, wherein the administration range is 2.5-200 mug, arformoterol or salt thereof, the administration range is 4-200 mug, the tiotropium bromide acts on muscarinic receptors on bronchial smooth muscle, the cholinergic action of acetylcholine released from parasympathetic nerve terminals can be inhibited, muscle tension is blocked, and bronchiectasis is generated, the arformoterol acts on β 2-receptors on cell membranes of the airway smooth muscle, so that the airway smooth muscle is dilated, the release of mast cells and basophil degranules and media is reduced, the permeability of capillaries is reduced, and the swinging of cilia on of airway epithelium is increased.
Description
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical preparation containing tiotropium bromide and arformoterol.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a Chronic bronchitis and/or emphysema characterized by airflow obstruction that can further progress to common Chronic Diseases of Pulmonary heart disease and respiratory failure. The incidence and mortality of COPD tends to increase due to factors such as air pollution and an increase in the number of smokers.
Bronchial asthma (asthma for short) is a chronic airway disease that is characterized by airway inflammation, increased mucus secretion, and airway hyperresponsiveness. Th2 cells, eosinophils, macrophages, neutrophils and other inflammatory factors, chemokines and the like are commonly involved in the inflammatory response of allergic asthma.
Some COPD or asthma patients are not effective on a single drug and are treated with a combination of different types of drugs.
The inhalation preparation is a drug-mechanical combination type preparation, and the normative operation of the inhalation device is also equally important when the normative administration is adhered to for a long time. When the single medicine is used, a patient needs to learn the use of different inhalation delivery systems, the operation difficulty and the burden of the patient are increased, the use is inconvenient, the medication compliance of the patient is poor, and the clinical effect is influenced.
Disclosure of Invention
In view of the deficiencies of the prior art, it is an object of the present invention to provide a pharmaceutical formulation comprising tiotropium bromide and arformoterol.
In order to achieve the above purpose, the solution of the invention is as follows:
a pharmaceutical formulation comprising tiotropium bromide and arformoterol, which comprises a tiotropium salt or a hydrate thereof and arformoterol or a salt thereof.
Wherein, the administration range of the tiotropium salt or the hydrate thereof is 2.5-200 mug, and the structure of the tiotropium salt is shown as the compound (I):
wherein, X-Is pharmaceutically acceptable anion selected from chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, etc,One or more of acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate, preferably bromide.
The administration range of the arformoterol or its salt is 4-200 mug, and the arformoterol has the structure shown in the compound (II):
the arformoterol salt is selected from more than one of tartrate, maleate, sulfate, hydrochloride, hydrobromide, phosphate, acetate, fumarate and citrate.
Among them, arformoterol is a long-acting β 2-receptor agonist (L ABA), which relaxes airway smooth muscle, reduces the release of mast cell and basophil degranulation and mediators, decreases permeability of microvasculature, and increases ciliary beat of airway epithelium by exciting β 2-receptors on the surface of airway smooth muscle and mast cell membrane.
Tiotropium bromide is a long-acting anticholinergic drug (L AMA) that inhibits the cholinergic (bronchoconstrictive) action of acetylcholine released from the distal parasympathetic nerve terminals by binding to muscarinic receptors on the bronchial smooth muscle and can last for over 24 hours.
For treatment of asthma or COPD, L AMA/L ABA dual therapy may improve lung function, symptoms, health-related quality of life better than monotherapy, and further reduce the risk of acute exacerbation.
Preferably, compound (I) and compound (ii) are provided in a form suitable for sequential administration.
Preferably, compound (I) and compound (ii) are provided in a form suitable for simultaneous administration.
Preferably, at least one of compound (I) and compound (ii) is formulated with a pharmaceutically acceptable carrier or excipient.
Due to the adoption of the scheme, the invention has the beneficial effects that:
the arformoterol acts on β 2-receptors on cell membranes of airway smooth muscles to relax the airway smooth muscles, the tiotropium bromide acts on muscarinic receptors on bronchial smooth muscles to block muscular tension, and different mechanisms play the role of relaxing the bronchi when the two medicines are combined, so that acute exacerbation of patients with chronic obstructive pulmonary disease is reduced, and the all-cause mortality is reduced.
Detailed Description
The invention provides a pharmaceutical composition of a long-acting anticholinergic drug and a long-acting β 2-receptor agonist, in particular to a pharmaceutical preparation containing tiotropium bromide and arformoterol.
(1) Mode of administration
It is described in the patent publication CN107412229A, "combination of muscarinic receptor antagonist and β 2-adrenoceptor agonist", that the individual compounds of the pharmaceutical combination product may be administered sequentially or simultaneously in separate or combined pharmaceutical formulations/compositions, thus, compound (I) and compound (ii) may be formulated separately and provided in separate packages or devices, or the separately formulated components may be provided in a single package or device.
In a further aspect, the invention thus provides:
a pharmaceutical combination comprising separately provided compound (I) and compound (ii) for sequential or simultaneous administration.
A pharmaceutical combination comprising compound (I) and compound (ii) for sequential or simultaneous administration, provided separately but in the same package or device.
And a pharmaceutical combination comprising compound (I) and compound (II) mixed with each other for simultaneous administration.
(2) Pharmaceutical preparation
The administration range of the anticholinergic drug tiotropium salt or hydrate thereof in the pharmaceutical composition is 2.5-200 μ g, the administration range of β 2-receptor agonist arformoterol or salt thereof is 4-200 μ g, in order to effectively reach the lung, the particle size of the active substance needs to be controlled, the optimal particle size is usually 1-10 μm, preferably 1-5 μm, the active substance is generally pulverized and pulverized by a micronization process, common micronization equipment comprises an air flow pulverizer, a high-speed ball mill, a planetary ball mill, a disc mill and the like, and the equipment can drive particles in a container to mutually collide, extrude and rub through air flow, a stirring paddle, a grinding rod, a grinding ball, a container wall and the like to break loose active ingredients into particles with an inhalable size.
The invention provides an inhalation preparation of a combination of tiotropium bromide and arformoterol, which comprises an inhalation aerosol, an inhalation powder spray and an inhalation atomization liquid. The compositions may be prepared by any method well known in the art of pharmacy. Generally, the method comprises admixing the active ingredient with a carrier that constitutes one or more accessory ingredients. The compositions are generally prepared by: the active ingredient is mixed homogeneously and intimately with liquid carriers or \ and finely divided solid carriers, and the product is shaped, if necessary, to give the desired composition, for example to form agglomerated particles.
When the active ingredient of the composition is to be administered as an aerosol, it may be suspended or dissolved in a mixture of propellants, including hydrofluoroalkanes (preferably HFA227 and HFA134A, R-152A), carbon dioxide, nitrogen, propane, isobutane, where each propellant may be used in the composition alone or in admixture with other propellants. In this formulation, the preferred propellant is FA134 and or HFA 227; more preferably a mixture of HFA-134A and HFA-227, wherein the density of the mixture of HFA-134A and HFA-227 is the same as or similar to the density of the particles in which the composition is suspended: and optionally adding dispersant such as anhydrous alcohol, isopropanol, propylene glycol, etc., and surfactant such as oleic acid, polyvinylpyrrolidone, lecithin, tween, etc.
When the active ingredient of the composition is administered as an inhalation liquid (i.e., an inhalation spray), the optional solvent may be one or more of water, ethanol, propylene glycol, polyethylene glycol, glycerol, etc., or surfactant such as polyvinylpyrrolidone, oleic acid, ethyl oleate, lecithin, sorbitan fatty acid ester such as tween, etc., or osmotic pressure regulator such as glucose, sodium chloride, etc., or pH regulator such as EDTA sodium chelate, etc. may also be added.
When the active ingredient of the composition is administered as an inhaled powder spray, compound (I) and compound (ii) may be formulated with or without pharmaceutical carriers or additives, respectively.
Powder aerosols are generally prepared using carriers comprising mono-, di-or polysaccharides such as lactose, dextran, mannitol, glucose, arabinose, fructose, ribose, mannose, sucrose, trehalose, maltose or starch lactose may be used preferably lactose may be anhydrous lactose or α -lactose monohydrate dry powder compositions may contain, in addition to the active ingredient and the carrier, additional additives such as fine lactose, magnesium stearate, calcium stearate, leucine, acetylcysteine, glycine, phospholipids, aerosil and polyethylene glycol.
(3) Inhalation device
In the patent publication CN107412229A, "combination of muscarinic receptor antagonist and β -adrenoceptor agonist", it is described that a composition suitable for administration by inhalation may be placed in a plurality of sealed dose containers provided on a pharmaceutical package placed in a suitable inhalation container, which may be a tearable, peelable or otherwise openable container of one type at a time, as is known in the art, and the dose of dry powder composition is administered by inhalation at the inhalation port of the inhalation deviceTM、DISKUSTMDevice, marketed by GlaxoSmithKline, DISKUSTMInhalation devices are described, for example, in GB 2242134A.
Dry powder inhalation compositions may also be provided in inhalation devices as a filled reservoir, the device being provided with a metering mechanism to meter a dose of the composition from the reservoir to an inhalation channel where the metered dose can be inhaled by a patient at the inhalation port of the deviceTMDistha L ER from ScheringTMAnd Innovata C L ICKHA L ERTM。
Another delivery method for delivering a dry powder inhalable composition is to provide a metered dose of the composition in a capsule (one capsule for each dose), place the capsule within an inhalation device, and place the capsule within the inhalation device, typically by the patient, when neededTMAnd HANDIHA L ER from Boehringer IngelheimTM。
Furthermore, the delivery device allows to independently comprise compound (I) and compound (ii), optionally mixed with one or more excipients. The individual compounds of the combination may be administered simultaneously but stored separately, for example as described in WO 2003/061743Al, WO2007/012871a1 and/or WO 2007/068896. The delivery device allowing independent inclusion of the active components is an inhaler device having two medicament packages in the form of peelable blister strips, each package containing a pre-metered dose in a blister pocket located along its length. The device has internally calibrated mechanisms, each time the device is opened, the pusher opens each elongated pocket and positions the package so that each newly exposed dose of each pocket is adjacent to a manifold communicating with the intake of the device. When the patient inhales at the inhalation port, each dose is simultaneously carried from the bag in which it resides into the manifold and through the inhalation port into the patient's respiratory tract. Thus, each time the device is used, the patient will receive a dose of medicament from each medication packAn exemplary commercially available device of this type is E LL IPTA from GlaxoSmithKlineTMAnother device that allows for independent inclusion of different compounds is the Innovata DuOHA L ERTM. The individual compounds of the combination may also be administered sequentially but stored separately as a delivery system as described in publication CN 110237373A.
The present invention will be further described with reference to the following examples.
Example 1:
the pharmaceutical formulation of this example is:
carrying out micronization on the tiotropium bromide monohydrate raw material medicine and the arformoterol tartrate in a jet mill, wherein the grinding pressure is 0.6MPa, and the particle size D50 of the obtained product is below 5 mu m.
Commercial lactose purchased (DEF L H200) was fractionated using a classifier at a feed rate of 1-2kg/H, a feed pressure of 0.55-0.65MPa, a classifying rotation rate of 6500-7500rpm, and a secondary gas flow rate of 0.5-0.8Nm3/min。
According to the following mixture ratio, one third of lactose in required amount is taken to be manually mixed with weighed tiotropium bromide monohydrate bulk drug and arformoterol tartrate (shown in table 1) in a mixing cup for 10min, then the rest lactose is added, the mixture is filled in a mixing tank, a single-arm mixer is used for mixing for 30min, then the mixture is taken out, is manually mixed for 10min again, is moved into a three-dimensional mixer for mixing for 60min, then is taken out, is manually mixed for 10min again, and the mixed material is collected in a sealed bag after the mixing is finished.
TABLE 1 Components of pharmaceutical compositions
| Components | Ratio of occupation of | Content of single agent |
| Tiotropium bromide monohydrate | 0.21％ | 25μg |
| Arformoterol tartrate | 0.12％ | 15μg |
| α lactose monohydrate | 99.67％ | 12mg |
The above composition is filled into blisters and the filled blisters are assembled into a sultone inhaler.
Comparative example 1:
the pharmaceutical formulation of this comparative example was:
micronizing the tiotropium bromide monohydrate raw material medicine in a jet mill under the crushing pressure of 0.6MPa, wherein the particle size D50 of the obtained product is below 5 mu m.
Commercial lactose purchased (DEF L H200) was fractionated using a classifier at a feed rate of 1-2kg/H, a feed pressure of 0.55-0.65MPa, a classifying rotation rate of 6500-7500rpm, and a secondary gas flow rate of 0.5-0.8Nm3/min。
According to the following mixture ratio, one third of lactose in required amount and weighed tiotropium bromide monohydrate raw material medicine (shown in table 2) are manually mixed in a mixing cup for 10min, then the rest lactose is added, the mixture is filled in a mixing tank, a single-arm mixer is used for mixing for 30min, then the mixture is taken out, the mixture is manually mixed for 10min again, the mixture is moved into a three-dimensional mixer for mixing for 60min, then the mixture is taken out and manually mixed for 10min again, and the mixed material is collected in a sealed bag after the mixing is finished.
TABLE 2 Components of pharmaceutical compositions
| Components | Ratio of occupation of | Content of single agent |
| Tiotropium bromide monohydrate | 0.21％ | 25μg |
| α lactose monohydrate | 99.79％ | 12mg |
The above composition is filled into blisters and the filled blisters are assembled into a sultone inhaler.
Comparative example 2:
the pharmaceutical formulation of this comparative example was:
the arformoterol tartrate raw material medicine is micronized in a jet mill, the grinding pressure is 0.6MPa, and the particle size D50 of the obtained product is below 5 mu m.
Commercial lactose purchased (DEF L H200) was fractionated using a classifier at a feed rate of 1-2kg/H, a feed pressure of 0.55-0.65MPa, a classifying rotation rate of 6500-7500rpm, and a secondary gas flow rate of 0.5-0.8Nm3/min。
According to the following mixture ratio, one third of lactose in required amount and weighed arformoterol tartrate raw material medicine (shown in table 3) are manually mixed in a mixing cup for 10min, then the rest lactose is added, the mixture is filled in a mixing tank, a single-arm mixer is used for mixing for 30min, then the mixture is taken out, the mixture is manually mixed for 10min again, the mixture is moved into a three-dimensional mixer for mixing for 60min, then the mixture is taken out and manually mixed for 10min again, and the mixed material is collected in a sealed bag after the mixing is finished.
TABLE 3 Components in pharmaceutical compositions
| Components | Ratio of occupation of | Content of single agent |
| Arformoterol tartrate | 0.12％ | 15μg |
| α lactose monohydrate | 99.88％ | 12mg |
The above composition is filled into blisters and the filled blisters are assembled into a sultone inhaler.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. It will be readily apparent to those skilled in the art that various modifications to these embodiments and the generic principles defined herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above-described embodiments. Those skilled in the art should appreciate that many modifications and variations are possible in light of the above teaching without departing from the scope of the invention.
Claims (6)
1. A pharmaceutical formulation comprising tiotropium bromide and arformoterol, characterized in that: it comprises tiotropium salts or hydrates thereof, and arformoterol or salts thereof;
the administration range of the tiotropium salt or the hydrate thereof is 2.5-200 mug, and the structure of the tiotropium salt is shown as the compound (I):
wherein, X-Is a pharmaceutically acceptable anion;
the administration range of the arformoterol or the salt thereof is 4-200 mug, and the structure of the arformoterol is shown as a compound (II):
2. a pharmaceutical formulation containing tiotropium bromide and arformoterol according to claim 1, characterized in that: in compound (I), the pharmaceutically acceptable anion is selected from one or more of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate.
3. A pharmaceutical formulation containing tiotropium bromide and arformoterol according to claim 1, characterized in that: in the compound (ii), the salt of arformoterol is one or more selected from the group consisting of tartrate, maleate, sulfate, hydrochloride, hydrobromide, phosphate, acetate, fumarate and citrate.
4. A pharmaceutical formulation containing tiotropium bromide and arformoterol according to any one of claims 1 to 3, characterized in that: said compound (I) and said compound (ii) are provided in a form suitable for sequential administration.
5. A pharmaceutical formulation containing tiotropium bromide and arformoterol according to any one of claims 1 to 3, characterized in that: said compound (I) and said compound (ii) are provided in a form suitable for simultaneous administration.
6. A pharmaceutical formulation containing tiotropium bromide and arformoterol according to any one of claims 1 to 3, characterized in that: at least one of said compound (I) and said compound (II) is formulated with a pharmaceutically acceptable carrier or excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010406777.3A CN111481550A (en) | 2020-05-14 | 2020-05-14 | Pharmaceutical formulation containing tiotropium bromide and arformoterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010406777.3A CN111481550A (en) | 2020-05-14 | 2020-05-14 | Pharmaceutical formulation containing tiotropium bromide and arformoterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111481550A true CN111481550A (en) | 2020-08-04 |
Family
ID=71796689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010406777.3A Pending CN111481550A (en) | 2020-05-14 | 2020-05-14 | Pharmaceutical formulation containing tiotropium bromide and arformoterol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111481550A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115267024A (en) * | 2022-07-31 | 2022-11-01 | 浙江知一药业有限责任公司 | Pharmaceutical composition for treating respiratory system diseases and detection method thereof |
| WO2024051683A1 (en) * | 2022-09-05 | 2024-03-14 | 立生医药(苏州)有限公司 | Pharmaceutical composition for inhalation for preventing or treating respiratory disease |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201021792A (en) * | 2008-10-23 | 2010-06-16 | Sepracor Inc | Arformoterol and tiotropium compositions and methods for use |
| EP2682108A2 (en) * | 2012-07-05 | 2014-01-08 | Arven Ilac Sanayi Ve Ticaret A.S. | Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component |
| CN104918604A (en) * | 2012-10-23 | 2015-09-16 | 西普拉有限公司 | Pharmaceutical composition |
| CN105412122A (en) * | 2010-07-16 | 2016-03-23 | 希普拉有限公司 | Pharmaceutical composition comprising R(+) budesonide and one or more bronchodilators |
| CN106029051A (en) * | 2014-01-10 | 2016-10-12 | 尊严科学有限公司 | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| CN111110662A (en) * | 2018-10-30 | 2020-05-08 | 北京盈科瑞创新药物研究有限公司 | Method for preparing solution preparation for inhalation |
-
2020
- 2020-05-14 CN CN202010406777.3A patent/CN111481550A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201021792A (en) * | 2008-10-23 | 2010-06-16 | Sepracor Inc | Arformoterol and tiotropium compositions and methods for use |
| CN105412122A (en) * | 2010-07-16 | 2016-03-23 | 希普拉有限公司 | Pharmaceutical composition comprising R(+) budesonide and one or more bronchodilators |
| EP2682108A2 (en) * | 2012-07-05 | 2014-01-08 | Arven Ilac Sanayi Ve Ticaret A.S. | Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component |
| CN104918604A (en) * | 2012-10-23 | 2015-09-16 | 西普拉有限公司 | Pharmaceutical composition |
| CN106029051A (en) * | 2014-01-10 | 2016-10-12 | 尊严科学有限公司 | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| CN111110662A (en) * | 2018-10-30 | 2020-05-08 | 北京盈科瑞创新药物研究有限公司 | Method for preparing solution preparation for inhalation |
Non-Patent Citations (2)
| Title |
|---|
| JAMES DONOHUE等: "Addition of Arformoterol Tartrate (ARF), a Long-Acting β2 Agonist (LABA), to Tiotropium Bromide (TIO) Improves Outcomes of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With TIO Alone or Placebo (PBO)", 《CHEST》 * |
| TASHKIN, D. P等: "Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD", 《RESPIRATORY MEDICINE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115267024A (en) * | 2022-07-31 | 2022-11-01 | 浙江知一药业有限责任公司 | Pharmaceutical composition for treating respiratory system diseases and detection method thereof |
| WO2024051683A1 (en) * | 2022-09-05 | 2024-03-14 | 立生医药(苏州)有限公司 | Pharmaceutical composition for inhalation for preventing or treating respiratory disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018282427B2 (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
| US20100329996A1 (en) | Novel Combination of Therapeutic Agents | |
| AU2012266541A1 (en) | Combination comprising umeclidinium and a corticosteroid | |
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| CN111481550A (en) | Pharmaceutical formulation containing tiotropium bromide and arformoterol | |
| WO2021227868A1 (en) | Pharmaceutical composition preparation | |
| CA2838031A1 (en) | Dry powder inhaler compositions comprising umeclidinium | |
| US9795561B2 (en) | Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases | |
| CA2459493C (en) | New pharmaceutical compositions for inhalation | |
| WO2010097114A1 (en) | Novel combination of therapeutic agents | |
| CN115266987B (en) | Pharmaceutical composition for treating respiratory diseases | |
| CN115267024B (en) | Pharmaceutical composition for treating respiratory diseases and detection method thereof | |
| EP3335707B1 (en) | Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist | |
| NZ618166B2 (en) | Combination comprising umeclidinium and a corticosteroid | |
| TW201618759A (en) | Dry powder for inhalation formulation having improved stability of combined active ingredients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200804 |